Skip to main content

Advertisement

SpringerLink
Log in

Beneficial treatment with risedronate in long-term survivors after allogeneic stem cell transplantation for hematological malignancies

  • Original Article
  • Published:
Osteoporosis International Aims and scope Submit manuscript

Abstract

In this prospective randomized study we evaluated the effect of risedronate, an aminobisphosphonate, on bone mass and turnover in patients who had undergone allogeneic stem cell transplant (SCT) for hematological malignancies. Thirty-four patients (18 females, 16 males, age 32±10 years) with bone mineral density (BMD) ≤−1.5 SD as a T-score at least 6 months after SCT were treated with calcium 1 g/day and vitamin D 800 IU/day and randomized to receive (n=17, group 1) or not receive (n=17, group 2) oral risedronate 5 mg/day. The duration of treatment was 12 months. After 6 months, lumbar BMD increased by 4.4±1.6% in patients of group 1 and decreased by 4.3±1.5% in those of group 2 (P<0.05); at the femoral neck, BMD did not change significantly in patients of group 1 (+1.2±1.2%), while it decreased in those of group 2 (−4.3±2.1%; P<0.05). After 12 months, lumbar BMD further increased (+5.9±1.7%, P<0.05), compared to baseline in group 1 and slightly increased (+1.1±1.4%) in group 2. No further changes were observed at femoral neck in both groups. In conclusion, treatment with risedronate for 12 months increased BMD significantly at the lumbar spine and prevented further bone loss at the femoral neck in long-term survivors after allo-SCT.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Weilbaecher KN (2000) Mechanisms of osteoporosis after hematopoietic cell transplantation. Biol Blood Marrow Transplant 6:165–171

    CAS  Google Scholar 

  2. Katz IA, Epstein S. Perspectives (1992) Post-transplantation bone disease. J Bone Min Res 7:123–126

    CAS  Google Scholar 

  3. Schimmer AD, Minden MD, Keating A (2000) Osteoporosis after blood and marrow transplantation: clinical aspects. Biol Blood Marrow Transplant 6:175–181

    CAS  PubMed  Google Scholar 

  4. Tauchmanovà L, Serio B, Del Puente A, et al (2002) Long-lasting bone damage detected by dual energy x-ray absorptiometry, phalangeal osteosonogrammetry and in vitro growth of marrow stromal cells after allogeneic stem cell transplantation. J Clin Endocrinol Metab 87:5058–5065

    Google Scholar 

  5. Selleri C, Maciejewski JP, De Rosa G, et al (1991) Long-lasting decrease of marrow and circulating long-term culture initiating cells after allogeneic bone marrow transplant. Bone Marrow Transplant 23:1029–1037

    Article  Google Scholar 

  6. Banfi A, Podesta M, Fazzuoli L, et al (2001) High-dose chemotherapy shows a dose-dependent toxicity to bone marrow osteoprogenitors: a mechanism for post-bone marrow transplantation osteopenia. Cancer 92:2419–2428

    Article  CAS  PubMed  Google Scholar 

  7. Lee WY, Cho SW, Oh ES, et al (2002) The effect of bone marrow transplantation on the osteoblastic differentiation of human bone marrow stromal cells. J Clin Endocrinol Metab 87:329–335

    Google Scholar 

  8. Valimaki MJ, Kinnunen K, Volin L, et al (1991) A prospective study of bone loss and turnover after allogeneic bone marrow transplantation: effect of calcium supplementation with or without calcitonin. Bone Marrow Transplant 23:355–361

    Article  Google Scholar 

  9. Stern JM, Sullivan KM, Ott SM, et al (2001) Bone density loss after allogeneic hematopoietic stem cell transplantation: a prospective study. Biol Blood Marrow Transplant 7:257–264

    CAS  PubMed  Google Scholar 

  10. Kelly PJ, Atkinson K, Warld RL, Sambrook PN, Biggs JC, Eisman JA (1990) Reduced bone mineral density in men and women with allogenic bone marrow transplantation. Transplant 50:881–882

    CAS  Google Scholar 

  11. Kauppila M, Irjala K, Koskinen P, Pulkki K, Sonninen P, Viikari J, Remes K (1999) Bone mineral density after allogeneic marrow transplantation. Bone Marrow Transplant 24:885–889

    Google Scholar 

  12. Kashyap A, Kandel F, Yamauchi D, Palmer JM, Niland JC, Molina A, Fung H, Bhatia R, Krishnan A, Nademanee A, O’Donnell MR, Parker P, Rodriguez R, Snyder D, Spielberger R, Stein A, Nadler J, Forman SJ (2000) Effects of allogeneic bone marrow transplantation on recipient bone mineral density. A prospective study. Biol Blood Marrow Transplant 6:344–351

    CAS  PubMed  Google Scholar 

  13. Castaneda S, Carmona L, Carvajal I, et al (1997) Reduction of bone mass in women after bone marrow transplantation. Calcif Tissue Int 60:343–347

    Article  CAS  Google Scholar 

  14. Ebeling PR, Thomas DM, Erbas B, Hopper JL, Szer J, Grigg AP (1999) Mechanisms of bone loss following allogenic and autologous hemopoietic stem cell transplantation. J Bone Miner Res 14:342–350

    CAS  PubMed  Google Scholar 

  15. Buchs N, Helg C, Collao C, et al (2001) Allogeneic bone marrow transplantation is associated with a preferential femoral bone loss. Osteoporos Int 12:880–886

    Article  CAS  PubMed  Google Scholar 

  16. Castelo-Branco C, Rovira M, Pons F, et al (1996) The effect of hormone replacement therapy on bone mass in patients with ovarian failure due to bone marrow transplantation. Maturitas 23:307–312

    Article  CAS  PubMed  Google Scholar 

  17. Marcus R, Wong M, Heath H III, Stock JL (2002) Antiresorptive treatment of postmenopausal osteoporosis: comparison of study designs and outcomes in large clinical trials with fracture as an endpoint. Endocr Review 23:16–37

    CAS  Google Scholar 

  18. Delmas PD (2002) Treatment of postmenopausal osteoporosis. Lancet 8:2018–2026

    Article  Google Scholar 

  19. Cranney A, Tugwell P, Adachi J, et al (2002) The Osteoporosis Methodology Group and The Osteoporosis Research Advisory Group. Meta-analysis of risedronate for the treatments of postmenopausal osteoporosis. Endocr Review 23:517–523

    Article  CAS  Google Scholar 

  20. Reid DM, Adami S, Devogelaer JP, Chines AA (2001) Risedronate increases bone density and reduces vertebral fracture risk within 1 year in men on corticosteroid therapy. Calcif Tissue Int 69:242–247

    Article  CAS  PubMed  Google Scholar 

  21. Di Somma C, Colao A, Pivonello R, et al (1998) Effectiveness of chronic treatment with alendronate in the osteoporosis of Cushing’s disease. Clin Endocrinol (Oxf) 48:655–662

    Google Scholar 

  22. Cohen S, Levy RM, Keller M, et al (1999) Risedronate therapy prevents corticosteroid-induced bone loss. Arthritis Rheum 42:2309–2318

    Article  CAS  PubMed  Google Scholar 

  23. Watts NB (2001) Risedronate for the prevention and treatment of postmenopausal osteoporosis: results from recent clinical trials. Osteoporosis Int 12 [Suppl 3]:S17–22

  24. Taggart H, Bolognese MA, Lindsay R, et al (2002) Upper gastrointestinal tract safety of risedronate: a pooled analysis of nine clinical trials. Mayo Clin Proc 77:262–70

    CAS  PubMed  Google Scholar 

  25. del Puente A, Heyse SP, Mandes MG, et al (1998) Epidemiology of osteoporosis in women in southern Italy. Aging Clin Exp Res 10:53–58

    Google Scholar 

  26. Schulte C, Beelen DW, Schaefer UW, Mann K (2000) Bone loss in long-term survivors after transplantation of hematopoietic stem cells: a prospective study. Osteoporos Int 11:344–353

    Article  CAS  PubMed  Google Scholar 

  27. Massenkeil G, Fiene C, Rosan O, Michael R, Reisinger W, Arnold R (2001) Loss of bone mass and vitamin D deficiency after hematopoietic stem cell transplantation: standard prophylactic measures fail to prevent osteoporosis. Leukemia 15:1701–5

    CAS  PubMed  Google Scholar 

  28. Sullivan KM, Agura E, Anasetti C, et al (1991) Chronic graft-versus-host-disease and other late complications of bone marrow transplantation. Semin Hematol 28:250–259

    CAS  PubMed  Google Scholar 

  29. Reginster JY (2001) Risedronate increases bone mineral density and reduces the vertebral fracture incidence in postmenopausal women. Clin Exp Rheumatol 19:121–122

    CAS  PubMed  Google Scholar 

  30. Fogelman I, Ribot C, Smith R, et al (2000) Risedronate reverses bone loss in postmenopausal women with low bone mass: results from a multinational, double-blind, placebo-controlled trial. J Clin Endocrinol Metab 85:1895–1900

    CAS  PubMed  Google Scholar 

  31. Reginster JY, Minne HW, Sorensen OH, et al (2000) Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int 11:83–91

    CAS  PubMed  Google Scholar 

  32. Wallach S, Cohen S, Reid DM, Hughes RA, Hoskins DJ, Laan RF, Doherty, Maricic M, Rosen C, Brown J, Barton I, Chines AA (2000) Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tiss Int 67:277–285

    Article  CAS  Google Scholar 

  33. Reid DM, Hughes RA, Laan R, et al (2000) Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. J Bone Miner Res 15:1006–1013

    CAS  PubMed  Google Scholar 

  34. Di Somma C, Pivonello R, Loche S, Faggiano A, Klain M, Salvatore M, Lombardi G, Colao A (2003) Effect of 2 years of cortisol normalization on the impaired bone mass and turnover in adolescent and adult patients with Cushing’s disease: a prospective study. Clin Endocrinol 58:302–308

    Article  Google Scholar 

  35. Catargi B, Tabarin A, Basse-Cathalinant B, Ducassou D, Roger P (1996) Development of bone mineral density after cure of Cushing’s syndrome. Ann Endocrinol (Paris) 57:203–208

    Google Scholar 

  36. Fleisch H (1998) Bisphophonates: mechanisms of action. Endocr Rev 19:80–100

    CAS  PubMed  Google Scholar 

  37. Boyce RW, Paddock CL, Gleason JR, Sletsems WK, Eriksen EF (1995) The effects of risedronate on canine cancellous bone remodeling: three-dimensional kinetic reconstruction of the remodeling site. J Bone Miner Res 10:211–221

    CAS  PubMed  Google Scholar 

  38. Rogers MJ, Chilton KM, Coxon FP, et al (1996) Bisphophonates induce apoptosis in mouse macrophage-like cells in vitro by a nitric oxide-dependent mechanism. J Bone Miner Res 11:1482–1491

    CAS  PubMed  Google Scholar 

  39. Selander K, Lebenkcari P, Väänänen HKÄ (1994) The effects of bisphophonates on the resorption cycle of isolated osteoclasts. Calcif Tissue Int 55:368–375

    CAS  PubMed  Google Scholar 

  40. Fromigue O, Body JJ (2002) Bisphosphonates influence the proliferation and the maturation of normal human osteoblasts. J Endocrinol Invest 25:539–546

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Molecular and Clinical Endocrinology and Oncology, University Federico II of Naples, via S. Pansini 5, 80131, Naples, Italy

    L. Tauchmanovà, C. Di Somma, F. Orio Jr., G. Lombardi & A. Colao

  2. Division of Hematology, University Federico II of Naples, Naples, Italy

    C. Selleri, M. Esposito & B. Rotoli

  3. Department of Gynecology and Obstetrics, University Federico II of Naples, Naples, Italy

    G. Bifulco

  4. Department of Gynecology and Obstetrics, University of Catanzaro “Magna Graecia”, Catanzaro, Italy

    S. Palomba

Authors
  1. L. Tauchmanovà
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C. Selleri
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. Esposito
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. C. Di Somma
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. F. Orio Jr.
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. G. Bifulco
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. S. Palomba
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. G. Lombardi
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. B. Rotoli
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. A. Colao
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. Colao.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tauchmanovà, L., Selleri, C., Esposito, M. et al. Beneficial treatment with risedronate in long-term survivors after allogeneic stem cell transplantation for hematological malignancies. Osteoporos Int 14, 1013–1019 (2003). https://doi.org/10.1007/s00198-003-1520-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00198-003-1520-2

Keywords

Search

Navigation